Literature DB >> 17221328

Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

Jack Ansell1, Jennifer Hollowell, Vittorio Pengo, Fernando Martinez-Brotons, Jaime Caro, Ludovic Drouet.   

Abstract

BACKGROUND/
OBJECTIVES: Expert oral anticoagulation management is the key to good outcomes and is performed variably in different health care systems throughout the world. We set out to assess the quality of anticoagulation management in five countries in patients receiving vitamin K antagonists (VKAs) for stroke prophylaxis in chronic non-valvular atrial fibrillation (NVAF), and to compare the anticoagulation management practices in these countries. METHODS AND
RESULTS: This was a retrospective, multi-centre cohort study in the United States, Canada, France, Italy, and Spain. About 1,511 patients were randomly recruited from representative practices (routine medical care (RMC) in the US, Canada, and France; anticoagulation clinics in Italy and Spain) and data pertaining to their oral anticoagulation care were abstracted from their medical records. The predominant anticoagulant in use was warfarin in the US, Canada, and Italy; acenocoumarol in Spain; and fluindione in France. Documentation of care was poor in the US, Canada, and France, countries where RMC was studied. Percent INRs or time-in-therapeutic range was greater in the two anticoagulation clinic samples compared with the RMC samples.
CONCLUSION: Oral anticoagulation care varies considerably from country to country. Findings suggest that anticoagulation clinic care (ACC) may provide better outcomes as assessed by international normalized ratio (INR) time-in-range. Physicians tend to under treat more than over treat. Finally, documentation of care is often inadequate. Condensed Abstract Oral anticoagulation management (routine medical care or anticoagulation clinic care) was retrospectively assessed in 5 countries using a uniform, structured assessment tool. Major management differences were detected, especially between anticoagulation clinic care and routine care. Documentation was often a problem in the latter setting. Less time in therapeutic INR range was noted in routine medical care. Findings suggest that anticoagulation clinic care may provide better outcomes as assessed by international normalized ratio (INR) time-in-range. Physicians tend to under treat more than over treat. Finally, documentation of care is often inadequate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221328     DOI: 10.1007/s11239-006-9022-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  18 in total

1.  Short report: managing anticoagulation. Comparison of results at three primary care centres.

Authors:  Ross E G Upshur; Christine Papoushek; Denis Macdonald; Guilherme Dantas
Journal:  Can Fam Physician       Date:  2003-02       Impact factor: 3.275

2.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

3.  Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic.

Authors:  M A Chamberlain; N A Sageser; D Ruiz
Journal:  J Am Board Fam Pract       Date:  2001 Jan-Feb

4.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy.

Authors:  Daniel M Witt; Melanie A Sadler; Roberta L Shanahan; Georgann Mazzoli; Donald J Tillman
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

5.  Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities.

Authors:  G P Samsa; D B Matchar; L B Goldstein; A J Bonito; L J Lux; D M Witter; J Bian
Journal:  Arch Intern Med       Date:  2000-04-10

6.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

8.  Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey.

Authors:  Cary P Gross; Eric W Vogel; Abhay J Dhond; Cheryl B Marple; Roger A Edwards; Ole Hauch; Elizabeth A Demers; Michael Ezekowitz
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

9.  Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Authors:  E M Hylek; D E Singer
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

10.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

View more
  48 in total

1.  [Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].

Authors:  B Leithäuser; F Kasch; T Broemel; J-W Park
Journal:  Herz       Date:  2010-12       Impact factor: 1.443

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

4.  A higher international normalized ratio may be better for your patient.

Authors:  Harry Buller
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

5.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

6.  Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).

Authors:  Matthieu Plichart; Gilles Berrut; Nathalie Maubourguet; Claude Jeandel; Jean-Paul Emeriau; Joël Ankri; Hélène Bouvier; Geneviève Ruault; Olivier Hanon
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

7.  Outpatient management of oral anticoagulation therapy in patients with nonvalvular atrial fibrillation.

Authors:  Aida Kulo; Nedzad Mulabegović; Jasna Kusturica; Hasija Hadzić; Lejla Burnazović-Ristić; Maida Rakanović-Todić; Amila Mehmedović; Orhan Lepara
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

8.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Authors:  N A Limdi; H Wiener; J A Goldstein; R T Acton; T M Beasley
Journal:  Blood Cells Mol Dis       Date:  2009-03-17       Impact factor: 3.039

Review 9.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.

Authors:  Natalie Oake; Alison Jennings; Alan J Forster; Dean Fergusson; Steve Doucette; Carl van Walraven
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

10.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.